

1 **Efficacy of Intrawound Vancomycin in Prevention of Periprosthetic Joint Infection**
2 **After Primary Total Knee Arthroplasty**
3 *A Prospective Double-Blinded Randomized Control Trial*

4
5 Authors:
6

- 7 1. Praharsha Mulpur¹
8 Consultant Orthopaedic and Joint Replacement Surgeon
9 Praharshamulpur9@gmail.com
10
11 2. Tarun Jayakumar¹ [Corresponding Author]
12 Registrar, Arthroplasty
13 tarunjaykumar@gmail.com
14
15 3. Ramakanth R Yakkanti²
16 MD, Rothman Orthopaedic Institute
17 yakkanti1@gmail.com
18
19 4. Aditya Apte¹
20 Research Fellow, Division of Arthroplasty
21 dradityaapte@gmail.com
22
23 5. Kushal Hippalgaonkar¹
24 Consultant Orthopaedic and Joint Replacement Surgeon
25 kushalhippal@gmail.com
26
27 6. Adarsh Annapareddy¹
28 Consultant Orthopaedic and Joint Replacement Surgeon
29 dr.adarshannapareddy@gmail.com
30
31 7. A B Suhas Masilamani¹
32 Consultant Orthopaedic and Joint Replacement Surgeon
33 drsuhhas09@gmail.com
34
35 8. A V Gurava Reddy¹
36 Consultant and Chief Orthopaedic and Joint Replacement Surgeon
37 guravareddy@gmail.com
38

39 **Affiliations:**

- 40 1- Sunshine Bone and Joint Insitute, KIMS-Sunshine Hospitals, Hyderabad, India
41 2- Rothman Orthopedic Institute, Philadelphia
42

43
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

44 **ABSTRACT**

45

46 **Introduction:** Peri-prosthetic Joint Infection (PJI) after total knee arthroplasty (TKA) is a
47 devastating complication. Intra-wound vancomycin powder has been shown to reduce
48 infection rates in spine surgery. Previous studies on the efficacy of local vancomycin powder
49 in hip or knee arthroplasty are mostly retrospective case series. The aim of this prospective
50 RCT was to evaluate the efficacy and safety of intrawound vancomycin in preventing PJI
51 after primary TKA.

52 **Methods:** This study was a National Trial Registry-approved RCT of patients undergoing
53 primary TKA. 1022 patients were randomized to the study group (n=507, received 2g
54 intrawound vancomycin powder before arthrotomy closure) and control groups (n=515, no
55 local vancomycin). The minimum follow-up was 12-months. The primary outcome was PJI
56 rate. Secondary outcomes included surgical site infection (SSI) rates, incidence of revision
57 for PJI/SSI, and incidence of wound complications. High-risk groups (Obesity and Diabetes)
58 in both cohorts were also evaluated.

59 **Results:** The overall infection rate in 1022 patients was 0.66%. There was no significant
60 difference in PJI rate in the study group (0.2%) versus the control group (0.58%), p=0.264.
61 Reoperation rates in the study group (N=4;0.78%) and Control (N=5;0.97%) and SSI rates in
62 the study (N=1;0.2%) and control groups (N=2;0.38%) were comparable. The Vancomycin
63 cohort however demonstrated a significantly higher number of minor wound complications
64 (n=67;13.9%) compared to the control group (n=39;8.4%, p<0.05). There was no difference
65 in PJI/SSI rates or minor surgical complications among high-risk groups and no cases of
66 nephrotoxicity were reported in the study.

67 **Conclusion:** Intra-wound vancomycin powder does not appear to reduce PJI/SSI rate in
68 primary total knee arthroplasties, including high-risk groups. Although safe from a renal
69 perspective, intra-wound vancomycin was associated with an increase in postoperative
70 aseptic wound complications such as persistent wound drainage. Intra-wound vancomycin
71 may not be effective in reducing the rate of PJI in primary TKA.

72

73 **Keywords:** Infection; Arthroplasty; Knee; Prosthetic Joint Infection; Surgical site infection

74

75

76

77

78 INTRODUCTION

79 There is an ever-increasing global burden of primary total knee and total hip arthroplasty
80 procedures, with a significant increase in surgery numbers projected by the year 2030 (1–3).
81 With increasing numbers of primary total joint replacement surgeries, healthcare systems
82 across the world are poised to handle an increased burden of revision arthroplasty cases.
83 Worldwide, the reported incidence of PJI after total joint replacement is around 0.8-1.5%,
84 with a 1-2% PJI risk after TKA (4–6).

85

86 Periprosthetic joint infection (PJI) is one of the most common indications for revision after
87 TKA (7–9) posing a significant burden to the healthcare system (10,11). There has been
88 increasing interest in the use of local antibiotic powder in the joint before closure to prevent
89 local contamination and biofilm formation. The use of intrawound vancomycin in preventing
90 surgical site infections is well documented in spine surgery (12–14). There are some
91 published reports of the benefits of local vancomycin powder used in surgeries of the elbow,
92 foot and ankle surgery (15,16). However, its use and clinical benefit in total knee arthroplasty
93 is debatable.

94

95 The main postulated advantages of using local vancomycin powder are its relatively cheap
96 cost, favourable bacterial spectrum (MRSA, coagulase-negative staphylococci), high local
97 concentrations without systemic adverse effects (17,18). Systematic reviews and meta-
98 analyses on studies evaluating the use of vancomycin in primary total knee or hip arthroplasty
99 reported low-quality evidence with a high risk of study bias (19,20). No randomized control
100 trial (RCT) has evaluated the efficacy of local vancomycin powder in primary TKA.

101

102 The primary objective of this study was to evaluate the efficacy of intra-wound vancomycin
103 in reducing SSI or PJI rates in patients undergoing primary total knee arthroplasty. Secondary
104 objectives include the evaluation of wound-healing-related complications, incidence of
105 nephrotoxicity, and the influence of diabetes and obesity on outcomes.

106

107

108 Methods

109 This is an Institutional Review Board (IRB) approved prospective randomized, controlled
110 trial (RCT), and was prospectively registered with the National Central Trial Registry
111 (CTRI/2021/02/031310). This is a single-centre RCT of patients from a high-volume tertiary

112 care institute, who underwent primary total knee arthroplasty (TKA) for primary
113 osteoarthritis of the knee, between January 2021 and February 2022. The RCT was a parallel-
114 arm trial with a 1:1 allocation of patients into study and control groups. Study group patients
115 receive intra-articular 2g Vancomycin antibiotic powder before arthrotomy closure, control
116 group patients did not receive local vancomycin powder. The trial was conducted following
117 the guidelines of the Declaration of Helsinki on scientific studies involving human subjects.

118

119 All adult patients with primary osteoarthritis of the knee, consenting to primary manual jig-
120 based TKA were eligible for recruitment in this trial. This includes patients with primary OA,
121 with either varus or valgus deformity of the knee. Patients were excluded from the trial if
122 they met any of the following exclusion criteria- refusal to participate in the trial, intra-
123 operative findings suggestive of inflammatory arthropathy or non-specific synovitis, previous
124 knee surgeries, history of intra-articular knee injections within 3 years before surgery, known
125 allergy to Vancomycin, and if they were known cases of chronic immunosuppression
126 (secondary to human immuno-deficiency virus-HIV, malignancy or post-solid organ
127 transplant). Patients who used antibiotics for any cause, within 1-month leading up to surgery
128 were also excluded from the trial.

129

130 There were a total of 1208 eligible patients who underwent primary TKA during the study
131 period (January 2021 to January 2022). 56 patients declined to participate in the trial and a
132 further 24 patients were excluded due to exclusion criteria (12 patients used antibiotics for
133 Urinary tract infections, 8 patients with recent intra-articular knee visco-supplementation
134 injections and 4 patients with chronic immunosuppression). After exclusions, 1128 patients
135 were randomized to the study and control groups. 34 patients were excluded from the final
136 data analysis after randomization (16 deaths in the follow-up period, 18 cases with intra-
137 operative findings suggestive of inflammatory arthropathy or non-specific synovitis).

138

139 The final study cohorts consisted of 549 patients in the study group and 545 patients in the
140 Control group. There was a loss to follow-up of 42 patients (8%) in the study group and 30
141 patients (5.76%) in the control group, Final analysis included 507 subjects in the study group
142 and 515 subjects in the control group.

143

144 Eligible trial participants undergoing primary total knee arthroplasty were randomized (1:1
145 allocation by computer randomization) to receive either normal saline lavage with (study

146 group) or without (control group) intra-articular 2g Vancomycin powder prior to arthrotomy
147 closure. All patients were operated on at the same institute, in laminar flow operating rooms.
148 Except for the use of vancomycin powder in the surgical wound, the operating procedures
149 and peri-operative protocols were common to both groups. The patients are blinded and
150 unaware of the assigned groups and follow-up evaluation for infection related complications
151 was performed by a blinded observer.

152
153 All cases in this trial received a standard antibiotic prophylaxis protocol, which includes 3
154 peri-operative intra-venous doses of 1.5g of Cefuroxime. The first dose was administered 1
155 hour before the skin incision and 2 doses were administered 8 hours and 24 hours after
156 surgery. None of the cases in this trial received prolonged Oral antibiotic use after surgery.
157 Skin preparation at the time of surgery was done with Chlorhexidine skin scrub (3M,
158 Avagard 4% Chlorhexidine Scrub). TKA was performed through a medial para-patellar
159 approach in all cases, under a tourniquet. Tourniquet was inflated from the time of the
160 incision till the cement was fully-set after final implantation. The knee joint was irrigated
161 with a total of 3 L of normal saline with pulse lavage before and after cementing of the
162 implant. All cases received bone cement without antibiotic impregnation (Palacos/ Stryker
163 Simplex low-viscosity cement). Patella was not resurfaced in any case, in either group. After
164 deflation of the tourniquet and haemostasis of bleeding vessels, the study group received 2g
165 vancomycin powder, which was placed into the medial and lateral joint gutters and
166 arthrotomy closed with No.2 Vicryl in an interrupted fashion followed by a continuous
167 STRATAFIX (Barbed-PDS) running stitch. Suction drains were not used in any case.

168
169 Post-operative blood investigations (Renal parameters, CBP) were obtained 24 hours after the
170 surgery. In all cases, wound dressing was changed 24 hours later in the PACU, with
171 MEPILEX surgical dressing (*Mepilex Border Post-op, Mölnlycke, Göteborg, Sweden*).
172 Patients in both groups received uniform rehabilitation with assisted walking and range of
173 motion exercises on the first postoperative day. Deep vein thrombosis prophylaxis was
174 common with low-Molecular weight heparin (LMWH) in the immediate postoperative period
175 and Oral Apixaban 2.5mg twice daily for 14 days following surgery. Surgical staple removal
176 is done between Day 14 and Day 21 after surgery. Staple removal after 21 days is considered
177 to be “Delayed staple/clip removal”. Patients were routinely followed up at 2 weeks, 4 weeks,
178 3 months and 6 months and 12 months after surgery.

179

180 Based on the criteria identified by Parvizi et al (21), early peri-prosthetic joint infection was
181 defined as an infection diagnosed within 90 days of surgery. Infection was diagnosed based
182 on the MSIS criteria and the 2018 Definition of Periprosthetic Hip and Knee Infection
183 consisting of 2 positive cultures (from an aspirate and/or at the time of debridement for PJI or
184 SSI), elevated serum ESR, CRP and elevated white cell counts in synovial fluid aspirates
185 ($>10,000$ cells/mm³), PMN percentage greater than 90% in the synovial aspirate(21,22).
186 Cases of possible infections based on the 2018 ICM (International Consensus Meeting)
187 scoring system were confirmed based on the findings of pus in aspirate and intra-operative
188 findings of purulence.

189 Surgical site infections and deep peri-prosthetic joint infections were considered major
190 surgical complications, necessitating re-operation. Minor complications included delayed
191 wound healing with or without dehiscence, delayed surgical staple removal, and stitch/suture
192 abscess (based on CDC Guidelines) necessitating oral antibiotic use. Persistent wound
193 drainage was defined as, wound drainage beyond 72-hours necessitating surgical dressing
194 change, based on previous definitions of persistent wound drainage (21,23).

195 Patients were also monitored in the peri-operative period for medical complications of
196 Myocardial infarction, DVT/PE, CVA and nephrotoxicity secondary to the use of
197 vancomycin.

198

199 **Statistical analysis**

200 Xu et al conducted a systematic review and meta-analysis of intra-wound vancomycin
201 powder used in primary total knee and hip arthroplasty(24). This meta-analysis concluded
202 that a minimum sample of 1000 patients was required for analysis, to conform to a decrease
203 of PJI rate from 2.74% to 1% in control versus study groups, with a power of 80% and 5%
204 significance level. Assuming a drop-out rate of 10%, we recruited over 1100 eligible subjects
205 for trial participation and randomization. Statistical analysis was performed using a 2-tailed
206 or independent samples t-test for continuous data parameters. The Chi-squared test or
207 Fisher's Exact test was used for categorical data parameters. Statistical analysis was
208 performed using SPSS Version 24 (International Business Machines- IBM, Armonk, NY).
209 Assuming a power of 80% and 95% confidence intervals, a p-value less than 0.05 was
210 considered significant.

211

212

213 **Results**

214 A total of 1022 patients were included in the final statistical analysis, with 507 patients in the
215 study group and 515 patients in the control group, after exclusions, loss to follow-up and
216 deaths. Demographic variables and baseline characteristics such as comorbidities, BMI, ASA
217 grading, and CCI grading were comparable between both groups and summarised in **Table.1**.
218 The mean tourniquet times and mean haemoglobin drop after surgery were also comparable
219 between both groups. The CONSORT Flowchart of participant recruitment is shown in
220 *Figure.1*

221

222 *Infection rates*

223 The overall infection rate in the study population was 0.66%. Periprosthetic joint infection
224 (PJI) was seen in 1 patient (0.19%) in the study group and 3 patients (0.58%) in the control
225 group, and the difference was not statistically significant. Surgical site infection (SSI) was
226 reported in 1 (0.19%) patient in the study group and 2 patients (0.38%) in the control group. 2
227 patients in the study group had periprosthetic fractures of the distal femur during the follow-
228 up period and underwent ORIF. All complications in the trial are summarized in **Table 2**.

229

230 *Peri-prosthetic Joint Infections (PJI)*

231 In the study group, one patient (0.19%) underwent DAIR for a culture-negative PJI, 4 weeks
232 after surgery. This patient had elevated serum ESR, CRP and White cell counts and frank pus
233 aspirated from the joint before DAIR. In the control group, 3 patients (0.58%) underwent
234 DAIR, of which one patient had Staphylococcus aureus isolated, and later went on to have a
235 2-stage revision due to the persistence of infection. The other two patients had culture-
236 negative PJI and underwent DAIR.

237

238 *Surgical Site Infections (SSI)*

239 One patient in the study group presented with an early SSI, with Staphylococcus epidermidis
240 the pathogenic organism isolated. This patient presented with persistent wound discharge
241 which was managed with superficial wound debridement and secondary closure and iv
242 antibiotics. 2 patients in the control group developed SSI, for which one patient underwent
243 debridement and secondary closure for local wound necrosis and the other patient developed
244 septic shock and Multi-Organ Dysfunction (MODS) following wound debridement at an
245 outside hospital, requiring hospitalization and intravenous antibiotics. The major
246 complications of PJI and SSI are summarized in **Table 3**.

247

248 ***Re-operation Rates***

249 Re-operation rates between both groups were found to be statistically comparable, with 4
250 0.78%) patients in the study group (1-PJI, 1-SSI, 2-Periprosthetic fracture) versus 5 cases
251 (0.97%) in the control group (3-PJI, 2-SSI). **(Table 2)**

252

253 ***Wound Complications***

254 The use of vancomycin was associated with a significantly higher number of minor wound
255 complications in the study group (n=67; 13.9%) compared to the control group (n=39; 8.4%,
256 p<0.05). Aseptic wound complications such as wound soakage, maceration and stitch abscess
257 were managed with regular dressings without any additional oral or intravenous antibiotic
258 use. Delayed suture removal (>3 weeks) was found to be similar in both groups and not
259 statistically significant. **(Table 2)**

260

261 ***Sub-group Analysis***

262 We evaluated differences in complication rates amongst patients of both groups based on
263 BMI and compared diabetics with non-diabetics. There was no difference in PJI/SSI rates or
264 minor surgical complications among high-risk groups, Diabetics versus non-diabetics, **(Table**
265 **4)** and high BMI vs normal BMI **(Tables 5 & 6)**.

266

267 ***Systemic Complications and Mortality***

268 The use of intra-wound vancomycin was not associated with acute kidney injury (defined as
269 an increase in serum creatinine levels by more than 0.3mg/dl within 48 hours)(25).

270 A total of 16 patients expired in the follow up period (10 patients in the study group versus 6
271 patients in the control group. One patient in the control group developed DVT with
272 Pulmonary embolism 45 days post-surgery and expired. Other patients expired secondary to
273 non-surgical factors (1 patient secondary to complications of CKD in the control group, 1
274 patient with Pleural effusion, 4 patients expired after treatment for trauma unrelated to the
275 prior knee arthroplasty). No cases of CVA, AMI, Nephrotoxicity, Ototoxicity or anaphylactic
276 reactions were observed or documented in the post-operative 90-day follow-up period.

277

278

279

280

281 **Discussion**

282 This randomised control trial did not demonstrate any additional clinical benefit of topical or
283 intra-wound vancomycin powder in preventing SSI/PJI in patients undergoing primary total
284 knee arthroplasty. On the contrary, there was a significant increase in wound healing
285 complications in the study group, with a significantly higher incidence of persistent wound
286 discharge and stitch abscess compared to the control group.

287

288 PJI after TKA bears a heavy toll on the patient and contributes to the economic burden on the
289 healthcare systems (6,11). The use of local antibiotic powder in orthopaedic surgery is not
290 new, with several reports of benefits in spine surgery (12–14,19,26). However, most of these
291 studies were retrospective and non-randomised. Tubaki et al published the only RCT on the
292 use of vancomycin in spine surgery and concluded that there was no difference in infection
293 rates with the use of vancomycin (27).

294

295 The role of topical or intra-wound vancomycin in primary total knee arthroplasty is
296 undecided, with studies both supporting and refuting the efficacy of vancomycin in reducing
297 post-operative PJI rates.

298

299 Heckman et al (28) published a meta-analysis and systematic review of intra-wound
300 vancomycin in total hip and knee arthroplasty with evidence demonstrating lower infection
301 rates with the use of vancomycin. However, all 6 studies included in the meta-analysis were
302 retrospective case series with Level-III evidence. Xu H et al published their meta-analysis of
303 4607 patients reporting a reduced PJI rate with the use of vancomycin but a higher incidence
304 of local wound complications and superficial surgical site infections (24). Our trial had
305 similar findings of a higher incidence of minor complications such as persistent wound
306 drainage and stitch abscesses in the study group.

307

308 Although previous studies attempted to evaluate the efficacy of intra-wound vancomycin,
309 most were either underpowered due to the relatively low incidence of PJI, or suffered from
310 low quality evidence secondary to retrospective study designs or lack of randomization. To
311 the best of our knowledge, this study is the first prospective randomized control trial on the
312 use of intra-wound vancomycin in primary TKA.

313

314

315 *Effect of intra-wound vancomycin on PJI/SSI*

316 In this trial, the use of intra-wound vancomycin powder in primary TKA failed to show a
317 reduction in the incidence of PJI/SSI. Previously published studies also showed no decrease
318 in the incidence of PJI with local vancomycin use (29,30)(31). On the contrary, Winkler et al
319 showed a statistically significant decrease in PJI in primary TKA. In the same study,
320 however, there was only a trend towards decreased PJI with local antibiotic administration in
321 THA and revision TKA/THA without statistical significance (32). The main limitation of this
322 report was the retrospective study design and heterogeneity of the study population which
323 included both primary and revision knee or hip arthroplasty, with varying intra-operative
324 protocols.

325
326 Most studies reporting reduced infection rates with the use of intra-wound vancomycin were
327 retrospective (33,34). Otte et al in their study of 1640 patients showed that 1g of intra-wound
328 vancomycin significantly reduced the incidence of PJI in both primary and revision scenarios
329 for both hips and knees (35). Patel et al also reported that intra-wound vancomycin was both
330 safe and effective in reducing rates of early PJI in both primary hip and knee arthroplasties
331 (36).

332
333 A meta-analysis by Peng et al, which included 4512 patients in 9 studies, also recommended
334 the use of vancomycin powder to reduce the incidence of PJI without modifying the bacterial
335 spectrum (37). A recent systematic review of 3371 patients did not demonstrate a significant
336 reduction in PJI in patients receiving vancomycin (38). This was similar to the findings of the
337 current trial.

338
339 This trial also showed a statistically significant increase in minor wound complications such
340 as persistent wound drainage and stitch abscesses with the use of vancomycin. However, this
341 should be interpreted with caution, as the trial may be underpowered to evaluate minor
342 complications. Similar wound complications were also reported in previously published
343 studies (20,24,26,33). The exact cause of this has not been determined but has been attributed
344 to the crystalline nature of the vancomycin salt, low pH of the vancomycin solution or as a
345 part of the body's inflammatory response to the vancomycin which leads to seroma formation
346 and subsequent wound complications (39). The aseptic wound complications in our study
347 were managed using repeated sterile wound dressings without the routine use of antibiotics.

348 Management of persistent wound drainage and breakdown can vary with some institutes
349 opting for wound debridement and secondary closure in the operation theatre (20,33).

350

351 *Use of intra-wound vancomycin in diabetics and other high-risk groups*

352 The use of vancomycin did not appear to significantly influence SSI/PJI rates in diabetics
353 versus non-diabetics in the study population. There was no difference in outcomes based on
354 the BMI classification of patients.

355

356 The strengths of this study include the prospective randomised study design, the trial
357 performed at a single high-volume arthroplasty institute with a standardised protocol
358 followed in all cases and a very low attrition during the follow-up period.

359

360 This study has some limitations. Firstly, this study is powered to detect a 1.7% difference in
361 the PJI rates between the study and control groups. The trial is not adequately powered to
362 detect smaller differences in PJI rates. The study may be underpowered for the minor
363 complications such as prolonged wound drainage and delayed wound healing. This calls for
364 large-volume multi-centre RCTs, with uniform protocols in peri-operative management.
365 Registry-based studies will be high-powered but subject to bias due to varying institutional
366 protocols in the asepsis procedures and antibiotic policies. Secondly, the results in this trial
367 are based on data from a single institute. Although the surgical technique, aseptic precautions
368 and antibiotic policy have been standardised across the study population, the findings may
369 not be generalizable to other institutions dissimilar to ours. Other limitations include sub-
370 analysis of other factors potentially contributing to PJI rate such as smoking or individual
371 comorbidities, which were not independently evaluated.

372

373 **CONCLUSION**

374 Intra-wound vancomycin powder application does not appear to reduce PJI/SSI rate in
375 primary total knee arthroplasties, including in high-risk groups. The use of intra-wound
376 vancomycin was associated with an increase in postoperative aseptic wound complications
377 such as persistent wound drainage. Intra-wound vancomycin may not be effective in reducing
378 the rate of PJI in primary TKA.

379

380

381

382 REFERENCES

- 383 1. Ackerman IN, Bohensky MA, Zomer E, Tacey M, Gorelik A, Brand CA, et al. The
384 projected burden of primary total knee and hip replacement for osteoarthritis in
385 Australia to the year 2030. *BMC Musculoskelet Disord*. 2019 Feb;20(1):90.
- 386 2. Kim TW, Kang S-B, Chang CB, Moon S-Y, Lee Y-K, Koo K-H. Current Trends and
387 Projected Burden of Primary and Revision Total Knee Arthroplasty in Korea Between
388 2010 and 2030. *J Arthroplasty*. 2021;36(1):93–101.
- 389 3. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip
390 and knee arthroplasty in the United States from 2005 to 2030. *J Bone Joint Surg Am*.
391 2007 Apr;89(4):780–5.
- 392 4. Springer BD, Cahue S, Etkin CD, Lewallen DG, McGrory BJ. Infection burden in total
393 hip and knee arthroplasties: an international registry-based perspective. *Arthroplast*
394 *today*. 2017 Jun;3(2):137–40.
- 395 5. Kapadia BH, Berg RA, Daley JA, Fritz J, Bhave A, Mont MA. Periprosthetic joint
396 infection. *Lancet (London, England)*. 2016 Jan;387(10016):386–94.
- 397 6. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection burden for hip and
398 knee arthroplasty in the United States. *J Arthroplasty*. 2008 Oct;23(7):984–91.
- 399 7. Clohisy JC, Calvert G, Tull F, McDonald D, Maloney WJ. Reasons for revision hip
400 surgery: a retrospective review. *Clin Orthop Relat Res*. 2004 Dec;(429):188–92.
- 401 8. Fehring TK, Odum S, Griffin WL, Mason JB, Nadaud M. Early failures in total knee
402 arthroplasty. *Clin Orthop Relat Res*. 2001 Nov;(392):315–8.
- 403 9. Vessely MB, Whaley AL, Harmsen WS, Schleck CD, Berry DJ. The Chitranjan
404 Ranawat Award: Long-term survivorship and failure modes of 1000 cemented
405 condylar total knee arthroplasties. *Clin Orthop Relat Res*. 2006 Nov;452:28–34.
- 406 10. Premkumar A, Kolin DA, Farley KX, Wilson JM, McLawhorn AS, Cross MB, et al.
407 Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in
408 the United States. *J Arthroplasty*. 2021 May;36(5):1484-1489.e3.
- 409 11. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of
410 periprosthetic joint infection in the United States. *J Arthroplasty*. 2012 Sep;27(8
411 Suppl):61-5.e1.
- 412 12. Dodson V, Majmundar N, Swantic V, Assina R. The effect of prophylactic
413 vancomycin powder on infections following spinal surgeries: a systematic review.
414 *Neurosurg Focus*. 2019 Jan;46(1):E11.
- 415 13. Caroom C, Tullar JM, Benton EGJ, Jones JR, Chaput CD. Intrawound vancomycin

- 416 powder reduces surgical site infections in posterior cervical fusion. *Spine (Phila Pa*
417 *1976)*. 2013 Jun;38(14):1183–7.
- 418 14. Bakhsheshian J, Dahdaleh NS, Lam SK, Savage JW, Smith ZA. The use of
419 vancomycin powder in modern spine surgery: systematic review and meta-analysis of
420 the clinical evidence. *World Neurosurg*. 2015 May;83(5):816–23.
- 421 15. Yan H, He J, Chen S, Yu S, Fan C. Intra-wound application of vancomycin reduces
422 wound infection after open release of post-traumatic stiff elbows: a retrospective
423 comparative study. *J shoulder Elb Surg*. 2014 May;23(5):686–92.
- 424 16. Wukich DK, Dikis JW, Monaco SJ, Strannigan K, Suder NC, Rosario BL. Topically
425 Applied Vancomycin Powder Reduces the Rate of Surgical Site Infection in Diabetic
426 Patients Undergoing Foot and Ankle Surgery. *Foot ankle Int*. 2015 Sep;36(9):1017–24.
- 427 17. Johnson JD, Nessler JM, Horazdovsky RD, Vang S, Thomas AJ, Marston SB. Serum
428 and Wound Vancomycin Levels After Intra-wound Administration in Primary Total
429 Joint Arthroplasty. *J Arthroplasty*. 2017 Mar;32(3):924–8.
- 430 18. Burdon DW. Principles of antimicrobial prophylaxis. *World J Surg*. 1982
431 May;6(3):262–7.
- 432 19. Fleischman AN, Austin MS. Local Intra-wound Administration of Powdered
433 Antibiotics in Orthopaedic Surgery. *J bone Jt Infect*. 2017;2(1):23–8.
- 434 20. Hanada M, Nishikino S, Hotta K, Furuhashi H, Hoshino H, Matsuyama Y. Intra-wound
435 vancomycin powder increases post-operative wound complications and does not
436 decrease periprosthetic joint infection in primary total and unicompartmental knee
437 arthroplasties. *Knee Surg Sports Traumatol Arthrosc*. 2019 Jul;27(7):2322–7.
- 438 21. Parvizi J, Gehrke T, Chen AF. Proceedings of the International Consensus on
439 Periprosthetic Joint Infection. *Bone Joint J*. 2013 Nov;95-B(11):1450–2.
- 440 22. Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C, Chen AF, et al. The 2018
441 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and
442 Validated Criteria. *J Arthroplasty*. 2018 May;33(5):1309-1314.e2.
- 443 23. Ghanem E, Heppert V, Spangehl M, Abraham J, Azzam K, Barnes L, et al. Wound
444 management. *J Orthop Res Off Publ Orthop Res Soc*. 2014 Jan;32 Suppl 1:S108-19.
- 445 24. Xu H, Yang J, Xie J, Huang Z, Huang Q, Cao G, et al. Efficacy and safety of
446 intra-wound vancomycin in primary hip and knee arthroplasty. *Bone Joint Res*. 2020
447 Nov;9(11):778–88.
- 448 25. Makris K, Spanou L. Acute Kidney Injury: Definition, Pathophysiology and Clinical
449 Phenotypes. *Clin Biochem Rev*. 2016 May;37(2):85–98.

- 450 26. Kang DG, Holekamp TF, Wagner SC, Lehman RAJ. Intrasite vancomycin powder for
451 the prevention of surgical site infection in spine surgery: a systematic literature
452 review. *Spine J.* 2015 Apr;15(4):762–70.
- 453 27. Tubaki VR, Rajasekaran S, Shetty AP. Effects of using intravenous antibiotic only
454 versus local intrawound vancomycin antibiotic powder application in addition to
455 intravenous antibiotics on postoperative infection in spine surgery in 907 patients.
456 *Spine (Phila Pa 1976).* 2013 Dec;38(25):2149–55.
- 457 28. Heckmann ND, Mayfield CK, Culvern CN, Oakes DA, Lieberman JR, Della Valle CJ.
458 Systematic Review and Meta-Analysis of Intrawound Vancomycin in Total Hip and
459 Total Knee Arthroplasty: A Call for a Prospective Randomized Trial. *J Arthroplasty.*
460 2019 Aug;34(8):1815–22.
- 461 29. Koutalos AA, Drakos A, Fyllos A, Doxariotis N, Varitimidis S, Malizos KN. Does
462 Intra-Wound Vancomycin Powder Affect the Action of Intra-Articular Tranexamic
463 Acid in Total Joint Replacement? *Microorganisms.* 2020 May;8(5).
- 464 30. Yavuz IA, Oken OF, Yildirim AO, Inci F, Ceyhan E, Gurhan U. No effect of
465 vancomycin powder to prevent infection in primary total knee arthroplasty: a
466 retrospective review of 976 cases. *Knee Surg Sports Traumatol Arthrosc.* 2020
467 Sep;28(9):3055–60.
- 468 31. Khatri K, Bansal D, Singla R, Sri S. Prophylactic intrawound application of
469 vancomycin in total knee arthroplasty. *J Arthrosc Jt Surg [Internet].* 2017;4(2):61–4.
470 Available from:
471 <https://www.sciencedirect.com/science/article/pii/S2214963517300330>
- 472 32. Winkler C, Dennison J, Wooldridge A, Larumbe E, Caroom C, Jenkins M, et al. Do
473 local antibiotics reduce periprosthetic joint infections? A retrospective review of 744
474 cases. *J Clin Orthop trauma.* 2018 Mar;9(Suppl 1):S34–9.
- 475 33. Dial BL, Lampley AJ, Green CL, Hallows R. Intrawound Vancomycin Powder in
476 Primary Total Hip Arthroplasty Increases Rate of Sterile Wound Complications. *Hip*
477 *pelvis.* 2018 Mar;30(1):37–44.
- 478 34. Xu X, Zhang X, Zhang Y, Chen C, Yu H, Xue E. Role of intra-wound powdered
479 vancomycin in primary total knee arthroplasty. *Orthop Traumatol Surg Res.* 2020
480 May;106(3):417–20.
- 481 35. Otte JE, Politi JR, Chambers B, Smith CA. Intrawound Vancomycin Powder Reduces
482 Early Prosthetic Joint Infections in Revision Hip and Knee Arthroplasty. *Surg*
483 *Technol Int.* 2017 Feb;30:284–9.

- 484 36. Patel NN, Guild GN 3rd, Kumar AR. Intrawound vancomycin in primary hip and knee
485 arthroplasty: a safe and cost-effective means to decrease early periprosthetic joint
486 infection. *Arthroplast today*. 2018 Dec;4(4):479–83.
- 487 37. Peng Z, Lin X, Kuang X, Teng Z, Lu S. The application of topical vancomycin powder
488 for the prevention of surgical site infections in primary total hip and knee arthroplasty:
489 A meta-analysis. *Orthop Traumatol Surg Res*. 2021 Jun;107(4):102741.
- 490 38. Wong MT, Sridharan SS, Davison EM, Ng R, Desy NM. Can Topical Vancomycin
491 Prevent Periprosthetic Joint Infection in Hip and Knee Arthroplasty? A Systematic
492 Review. *Clin Orthop Relat Res*. 2021 Aug;479(8):1655–64.
- 493 39. Hoelen DWM, Tjan DHT, van Vugt R, van der Meer YG, van Zanten ARH. Severe
494 local vancomycin induced skin necrosis. Vol. 64, *British journal of clinical*
495 *pharmacology*. England; 2007. p. 553–4.
- 496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517

518 **List of Tables**

Characteristics	Study Group N=507	Control Group N=515	p-value
Mean Age (SD)	61.7 (7.52)	61.4 (7.39)	0.520 *
Mean BMI (SD)	28.5 (4.49)	28.4 (4.52)	0.722 *
Mean Pre-op Haemoglobin (SD)	12.2 (1.41)	12.3 (1.33)	0.243 *
Mean Post-op Haemoglobin (SD)	10.3 (1.34)	10.4 (1.24)	0.215 *
Mean drop in Haemoglobin (SD)	-1.96 (1.143)	-1.91 (1.111)	0.478 *
Mean ASA (SD)	2.02 (0.143)	2.01 (0.186)	0.336 *
Mean Tourniquet Time (min) (SD)	70.2 (16.35)	71.1 (21.91)	0.457 *
Smoking N (%)	58 (11.44)	60 (11.65)	0.916 *
CCI Risk Classification			
Mild risk	324 (63.9)	330 (64.07)	0.278 †
Moderate risk	156 (30.76)	164 (31.84)	
High Risk	27 (5.34)	21 (4.09)	
Mean CCI (SD)	2.3 (1.15)	2.2 (1.14)	0.163 *
Gender Female N (%)	360 (71)	358 (69.51)	0.586 †
Male N (%)	147 (29)	157 (30.49)	
Diabetics N (%)	170 (33.53)	161 (31.26)	0.438 †
Hypothyroidism N (%)	85 (16.76)	92 (17.86)	0.642 †
CKD N (%)	2 (0.39)	4 (0.77)	0.424 †
ASA N (%) ASA I	6 (1.2)	10 (1.94)	0.220 †
N (%) ASA II	491 (96.84)	492 (95.53)	
N (%) ASA III	10 (1.96)	13 (2.53)	

519 * independent samples t-test, † Chi-square test

520 **Table.1.** Demographic and Baseline Characteristics of the study population

521

	Study Group N(%)	Control Group N(%)	p-value
Major Complications			
SSI N (%)	1	2	0.264 †
PJI (DAIR)	1	3	
Periprosthetic fracture	2	0	
Minor Complications			
Persistent Wound Drainage	43 (8.48)	26 (5.04)	0.010 †
Stitch Abscess	20 (3.94)	13 (2.52)	0.945 †
Delayed stitch removal (>3 weeks)	36 (7.1)	36 (6.99)	
Medical Complications			
Septic shock and MODS	0	1	NS †
DVT	0	1	
CVA	0	0	
Acute kidney injury/ Nephrotoxicity	0	0	
Cardiac complications	0	0	

522

†Chi-square test

523 **Table 2:** *Summary of complications in the study population*

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

Patient	Age Range	CCI	Time to Second surgery (weeks)	Culture report	Diagnosis	Treatment
Study						
1	51-60	1	5	No growth	PJI	DAIR
2	51-60	1	6	No growth	SSI	Debridement and secondary suturing
Control						
1	61-70	4	13	S. aureus	PJI	<ul style="list-style-type: none"> • DAIR • Two-stage revision
2	61-70	2	20	No growth	PJI	DAIR
3	61-70	2	6	No growth	PJI	DAIR
4	61-70	2	12	S. epidermidis	SSI	Debridement and secondary suturing
5	61-70	3	16	No growth	SSI	Debridement and secondary suturing Septic shock and MODS

539
540
541
542
543
544
545
546

Table 3: *Clinical summary of PJI and SSI cases*

547
548
549

	Study Group n (%)	Control Group n (%)	p-value
Number of Diabetics	170 (33.5)	161 (31.26)	0.444 †
Mean HbA1C (SD)	6.6 (2.04)	6.8 (1.95)	0.109 *
DM-CCI grading			
Mild	61 (35.9)	61 (37.9)	0.439 †
Moderate	88 (51.8)	87 (54.0)	
Severe	21 (12.4)	13 (8.1)	
Mean CCI (SD)	3.0 (1.03)	2.9 (1.14)	0.141 *
Infection rates			
Major Complications			
SSI	0	0	0.160 †
PJI (DAIR)	0	2	
Minor Complications			
Maceration, n (%)	9 (5.3)	6 (3.5)	0.329 †
Stitch Abscess, n (%)	15 (9.3)	4 (2.5)	
Delayed staple removal (>3 weeks) n (%)	36 (7.5)	36 (7.3)	0.942 †

550 * independent samples t-test, † Chi-square test

551 **Table 4:** *Sub-group analysis of outcomes in the high-risk diabetic patients in both groups*

552
553
554
555
556
557

558

	Study Group Minor complications n (%)	Control Group Minor complications n (%)	p-value
BMI grading			0.759 †
Normal	16 (26.2)	11 (29.7)	
Overweight	24 (39.3)	16 (43.3)	
Class I Obese	15 (24.6)	5 (13.5)	
Class II Obese	5 (8.2)	4 (10.8)	
Class III Obese	1 (1.6)	1 (2.7)	
Total	61 (100.0)	37 (100.0)	

559 † Chi-square test

560 **Table 5:** *Sub-group analysis of minor complications based on the classification of obesity*

561

562

	Study Group Major complications n (%)	Control Group Major complications n (%)	p-value
BMI grading			0.507 †
Normal	1 (25.0)	0 (0.0)	
Overweight	2 (50.0)	3 (60.0)	
Class I Obese	1 (25.0)	2 (40.0)	
Class II Obese	0 (0.0)	0	
Class III Obese	0 (0.0)	0	

563 † Chi-square test

564 **Table 6:** *Sub-group analysis of major complications based on the classification of obesity*

ENROLMENT

Assessed for Eligibility
(n=1208)

Excluded (n= 80)

- Declined to participate (n=56)
- Recent antibiotic usage (n=12)
- Intra-articular injections (n=8)
- Chronic immunosuppression (n=4)

Randomised (n= 1128)

Vancomycin (n=564)

Non-Vancomycin (n=564)

Excluded:

- Expired (n=10)
- Inflammatory arthritis/ Non-specific synovitis (n=5)

Excluded:

- Expired (n=6)
- Inflammatory arthritis/ Non-specific synovitis (n=13)

Analysed (n=549):

- Lost to Follow-up (n=42)

Analysed (n=545):

- Lost to Follow-up (n=30)

Final Analysed (n=507):

Final Analysed (n=515):